Custom Search

Wednesday, September 3, 2008

Pharma GMP Training Questions and Answers Complaints Recalls

Test Paper 5 – WHO GMP Training

Section – Complaints and Recalls

WHO GMP Training Questions and Answers Section for pharmaceutical manufacturing units :- Complaints and Recalls
In this post i am giving some questions of which you may know answers or you may like to know answers ,i have given few options for you to think up on , this is a very good tool to gather knowlede these questions are provided with answers at the bottem of every page ,so enjoy solving them, you can use these questions and answer sheet to train your personnels.



1. The principle for complaints handling is that:

.(A) .Companies need review only complaints about defective products.

.(B) .A company must review all complaints and other information about potentially defective product.

.(C) .Only complaints from pharmacists are reviewed.

.(D) .A company may find written procedures useful.


2. A person for handling complaints:

.(A) .Must be designated in writing by every company, large or small.

.(B) .Does not have to inform the QC manager that he or she is investigating a complaint.

.(C) .Can be appointed by the company from time to time as a complaint is received.

.(D) .Must be able to handle all incoming complaints alone.


3. The written procedures sop:

.(A) .Only describe who takes what action about a defective product.

.(B) .Do not need to consider the need for a recall.

.(C) .Do not need to record the original details but just the findings.

.(D) .Are required to handle a complaint concerning a possible product defect.


4. Any complaint concerning a product defect:

.(A) .Doesn’t need to involve the quality control department.

.(B) .Only needs thorough investigation if it will result in a product recall.

.(C) .Should be recorded with all the original product details, and thoroughly investigated.

.(D) .Doesn’t need to have all the details recorded so long as the results are recorded.


5. If a product defect is discovered in one batch:

.(A) .A company must have given consideration as to whether other batches should be reviewed.

.(B) .The company must investigate batches containing reprocessed product from that batch.

.(C) .There is great relief that no other batches need investigating.

.(D) .The investigation can be terminated by the medical director in case other batches are found to be defective.




6. After investigating a complaint:

.(A) .There is a need for follow-up action to maintain product confidence.

.(B) .The company is allowed to relax because the Sales Manager will talk to the person who complained and smooth things over.

.(C) .The company can do everything except consider a product recall.

.(D) .The company must take all appropriate follow-up action including a possible product recall.


7. All decisions and measures taken:

.(A) .Are only recorded if there is a product recall.

.(B) .Are recorded but do not need to be cross-referenced to original batch records.

.(C) .Should be recorded and referenced to the corresponding batch records.

.(D) .Small manufacturers can be exempted from this requirement by the Minister.


8. Complaint records:


.(A) .Only need to be reviewed to see if they are complete before an inspector comes.

.(B) .Should be regularly reviewed for any specific problems.

.(C) .Are reviewed only to see whether a product recall might be required.

.(D) .Don’t need to be written in small companies.


9. As the competent authority, you have to be informed:

.(A) .Only if a recall is possibly needed.

.(B) .If there are serious quality problems with a product.

.(C) .Only if there is a storage defect.

.(D) .Only if there are differences between what is registered and what has been done.


10. The principle for product recall is:

.(A) .Is not the responsibility of the manufacturer once the product has left the factory.

.(B) .That there should be a system to recall from the market, promptly and effectively, products known or suspected to be defective.

.(C) .To only to recall products that have been the subject of a complaint.

.(D) .That once the company has informed the National Drug Regulatory Authority, the Government will be responsible for the recall.




11. A person responsible for executing a product recall:

.(A) .Only needs to be identified when the company is faced with the need to do a recall.

.(B) .Can come from anywhere within the company that the company can spare at the time.

.(C) .If different from the authorized person must make the authorized person aware of any recall.

.(D) .May not have any enough support staff so the inspector should check carefully that the recall has been completed efficiently.


12. Established written recall procedures are:
.(A) .Regularly checked and updated for the organization of any recall activity.

.(B) .Developed only when if the Government insists on a recall.

.(C) .Not required for very small-scale manufacturers.

.(D) .Only required in commercial factories but not in Government-owned manufacturing facilities.


13. Distribution records:

.(A) .Are only required for product shipped within our own country.

.(B) .Do not need to record any batch numbers if they go to wholesalers.

.(C) .Should include product shipped for export and sent out for use in clinical trials and as medical samples those who received samples for clinical trials and medical samples.

.(D) .Are only accessible to the distribution manager.


14. The progress of the recall process:

.(A) .Includes a reconciliation between the delivered and recovered quantities of the products.

.(B) .Does not need to be recorded unless a Government Inspector says so.

.(C) .Only needs to be recorded when the job is done and there is some spare time available.

.(D) .Is recorded only by the QC manager.


15. Recalled products:

.(A) .Can be stored anywhere in the main warehouse if the company has a validated computer quarantine system.

.(B) .Have to be kept within the quarantine area.

.(C) .Can be left outside the factory because they are not worth anything.

.(D) .Must be kept in a secure segregated area while their fate is decided.


16. An example of a defect which may result in a recall is based on investigation :

.(A) .One empty blister pack in a batch of tablets.

.(B) .A readily visible cosmetic package fault.

.(C) .A product labelled with the incorrect name.

.(D) .A product which fails its shelf life studies.




17. A customer complaint that may result in a recall is:

.(A) .Contamination on the outside of a package which has minimal risk to the patient.

.(B) .Microbiological contamination of a sterile product.

.(C) .A small mark on the tablet coating.

.(D) .Microbial contamination of a non-sterile product which may have medical consequences.


18. A company knows it has a recall situation when:

.(A) .The National Drug Regulatory Authority informs them.

.(B) .The company discovers from its ongoing stability programme that a product has become hazardous to patients.

.(C) .A customer complaint indicates that the product is dangerous to health.

.(D) .The National Drug Regulatory Authority finds that a counterfeit or tampered product is on the market in the company’s packaging.

.(E) .All of the above.


19. A product with a life threatening defect must be recalled:

.(A) .Within the next 48 hours.

.(B) .Anytime within the next 5 working days.

.(C) .By all reasonable means whether in or out of business hours.

.(D) .Immediately if a patient has died but otherwise in normal business hours.


20. Complaints received by a company concerning product quality:

.(A) .Are mostly generated by people who want stock replacement of their expired pharmaceuticals.

.(B) .May be dealt with by the company if other more important work has been completed.

.(C) .Should be regularly reviewed by the top management of the company to see if there are any trends emerging.

.(D) .Are an important source of information enabling product quality to be improved.



Test Paper 5 – GMP Training

Section – Complaints and Recalls

Answers


.1. .B

.2. .A

.3. .D

.4. .C

.5. .A

.6. .D

.7. .C

.8. .B

.9. .B

.10. .B

.11. .C and D

.12. .A

.13. .C

.14. .A

.15. .D

.16. .C and D

.17. .B and D

.18. .E

.19. .C

.20. .C and D


I HOPE THIS TEST WILL REALY HELP YOU TO INCREASE YOUR KNOWLEDGE ON GMP

Following are some of articles which;will be useful for you in further understanding of aspects of sterile dosage form manufacturing

Pharmaceutical Validation

Cleen Room Classification

Pharmaceutical Industry

Pharmaceutical Manufacturing

Clinical Trials

Pharmaceutical

To Find Pharmaceutical jobs and make a Pharmaceutical careers see here pharmaceutical companies

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org